Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher E M Griffiths

Showing results (311-320 of 337) with videos related to

Pageof 34
Sort By:
American Journal of Human Genetics|May 6, 2014
AP1S3 mutations are associated with pustular psoriasis and impaired Toll-like receptor 3 traffickingNiovi Setta-Kaffetzi, Michael A Simpson, Alexander A Navarini, et al.
JAMA Dermatology|September 19, 2019
Association of Serum Ustekinumab Levels With Clinical Response in PsoriasisTeresa Tsakok, Nina Wilson, Nick Dand, et al.
The Journal of Investigative Dermatology|April 6, 2007
Filaggrin null alleles are not associated with psoriasisYiwei Zhao, Ana Terron-Kwiatkowski, Haihui Liao, et al.
Biorxiv : the Preprint Server for Biology|August 6, 2025
Glucocorticoids unleash immune-dependent melanoma control through inhibition of the GARP/TGF-β axisCharles H Earnshaw, Poppy Dunn, Shih-Chieh Chiang, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|June 17, 2026
Impact of Repeated Antigen Exposure on Humoral Tolerance: Antidrug Antibodies After Single-Dose Versus Multi-dose AdalimumabAnika M Valk, Jolinde van Strien, Ninotska Derksen, et al.
Clinical and Translational Science|April 30, 2026
Evaluation of a Therapeutic Drug Monitoring Strategy for Adalimumab in Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic StudyShan Pan, Teresa Tsakok, Ruoheng Wei, et al.
Dermatologic Clinics|September 24, 2021
Dermatology COVID-19 Registries: Updates and Future DirectionsEsther E Freeman, Grace C Chamberlin, Devon E McMahon, et al.
Clinical and Translational Science|January 30, 2020
Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic StudyShan Pan, Teresa Tsakok, Nick Dand, et al.
The Journal of Allergy and Clinical Immunology|December 23, 2018
HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasisNick Dand, Michael Duckworth, David Baudry, et al.
The Journal of Investigative Dermatology|November 12, 2021
Differences in Clinical Features and Comorbid Burden between HLA-C∗06:02 Carrier Groups in >9,000 People with PsoriasisKonstantinos Douroudis, Ravi Ramessur, Ines A Barbosa, et al.
Pageof 34

Showing results (311-320 of 337) with videos related to

Sort By:
Pageof 34
American Journal of Human Genetics|May 6, 2014
AP1S3 mutations are associated with pustular psoriasis and impaired Toll-like receptor 3 traffickingNiovi Setta-Kaffetzi, Michael A Simpson, Alexander A Navarini, et al.
JAMA Dermatology|September 19, 2019
Association of Serum Ustekinumab Levels With Clinical Response in PsoriasisTeresa Tsakok, Nina Wilson, Nick Dand, et al.
The Journal of Investigative Dermatology|April 6, 2007
Filaggrin null alleles are not associated with psoriasisYiwei Zhao, Ana Terron-Kwiatkowski, Haihui Liao, et al.
Biorxiv : the Preprint Server for Biology|August 6, 2025
Glucocorticoids unleash immune-dependent melanoma control through inhibition of the GARP/TGF-β axisCharles H Earnshaw, Poppy Dunn, Shih-Chieh Chiang, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|June 17, 2026
Impact of Repeated Antigen Exposure on Humoral Tolerance: Antidrug Antibodies After Single-Dose Versus Multi-dose AdalimumabAnika M Valk, Jolinde van Strien, Ninotska Derksen, et al.
Clinical and Translational Science|April 30, 2026
Evaluation of a Therapeutic Drug Monitoring Strategy for Adalimumab in Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic StudyShan Pan, Teresa Tsakok, Ruoheng Wei, et al.
Dermatologic Clinics|September 24, 2021
Dermatology COVID-19 Registries: Updates and Future DirectionsEsther E Freeman, Grace C Chamberlin, Devon E McMahon, et al.
Clinical and Translational Science|January 30, 2020
Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic StudyShan Pan, Teresa Tsakok, Nick Dand, et al.
The Journal of Allergy and Clinical Immunology|December 23, 2018
HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasisNick Dand, Michael Duckworth, David Baudry, et al.
The Journal of Investigative Dermatology|November 12, 2021
Differences in Clinical Features and Comorbid Burden between HLA-C∗06:02 Carrier Groups in >9,000 People with PsoriasisKonstantinos Douroudis, Ravi Ramessur, Ines A Barbosa, et al.
Pageof 34